Evaluation of the Cepheid Xpert MTB/RIF assay - PubMed (original) (raw)
Review
Evaluation of the Cepheid Xpert MTB/RIF assay
Thomas M Shinnick et al. Expert Rev Mol Diagn. 2015 Jan.
Abstract
The lack of capacity to provide laboratory confirmation of a diagnosis of tuberculosis disease (TB) is contributing to enormous gaps in the ability to find, treat and follow TB patients. WHO estimates that globally only about 57% of the notified new cases of pulmonary TB in 2012 and about 19% of rifampicin-resistant TB cases were laboratory confirmed. The Cepheid Xpert(®) MTB/RIF assay has been credited with revolutionizing laboratory testing to aid in the diagnosis of TB and rifampicin-resistant TB. This semi-automated test can detect both the causative agent of TB and mutations that confer rifampicin resistance from clinical specimens within 2 h after starting the test. In this article, we review the performance of the test, its pathway to regulatory approval and endorsement, guidelines for its use and lessons learned from the implementation of the test in low-burden, high-resource countries and in high-burden, low-resource countries.
Keywords: automated nucleic acid amplification; molecular detection of resistance; rifampicin resistance; tuberculosis.
Figures
Figure 1. Assay procedure for Xpert MTB/RIF
Diagram supplied by C Boehme, Foundation for Innovative New Diagnostics with permission [22].
Figure 2. Commercial tuberculosis products and development pipeline
Reproduced with permission from UNITAID [98].
Similar articles
- Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W. Scott LE, et al. PLoS Med. 2011 Jul;8(7):e1001061. doi: 10.1371/journal.pmed.1001061. Epub 2011 Jul 26. PLoS Med. 2011. PMID: 21814495 Free PMC article. - [Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in an intermediate-prevalence setting].
Ozkutuk N, Surucüoglu S. Ozkutuk N, et al. Mikrobiyol Bul. 2014 Apr;48(2):223-32. doi: 10.5578/mb.7456. Mikrobiyol Bul. 2014. PMID: 24819260 Turkish. - Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.
Mavenyengwa RT, Shaduka E, Maposa I. Mavenyengwa RT, et al. Infect Dis Poverty. 2017 Jan 11;6(1):13. doi: 10.1186/s40249-016-0213-y. Infect Dis Poverty. 2017. PMID: 28086955 Free PMC article. - Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N. Steingart KR, et al. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009593. doi: 10.1002/14651858.CD009593.pub2. Cochrane Database Syst Rev. 2013. PMID: 23440842 Free PMC article. Updated. Review. - Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.
Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. Kohli M, et al. Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2. Cochrane Database Syst Rev. 2018. PMID: 30148542 Free PMC article. Updated. Review.
Cited by
- Quality of Sputum Specimen Samples Submitted for Culture and Drug Susceptibility Testing at the National Tuberculosis Reference Laboratory-Uganda, July-October 2013.
Bulage L, Imoko J, Kirenga BJ, Lo T, Byabajungu H, Musisi K, Joloba M, Bloss E. Bulage L, et al. J Tuberc Res. 2015 Sep;3(3):97-106. J Tuberc Res. 2015. PMID: 35911866 Free PMC article. - A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.
The CRyPTIC Consortium. The CRyPTIC Consortium. PLoS Biol. 2022 Aug 9;20(8):e3001721. doi: 10.1371/journal.pbio.3001721. eCollection 2022 Aug. PLoS Biol. 2022. PMID: 35944069 Free PMC article. - Xpert MTB/RIF Use Is Associated With Earlier Treatment Initiation and Culture Conversion Among Patients With Sputum Smear-Negative Multidrug-Resistant Tuberculosis.
Kipiani M, Graciaa DS, Buziashvili M, Darchia L, Avaliani Z, Tabagari N, Mirtskhulava V, Kempker RR. Kipiani M, et al. Open Forum Infect Dis. 2021 Nov 6;8(12):ofab551. doi: 10.1093/ofid/ofab551. eCollection 2021 Dec. Open Forum Infect Dis. 2021. PMID: 34877367 Free PMC article. - Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics.
Adelman MW, McFarland DA, Tsegaye M, Aseffa A, Kempker RR, Blumberg HM. Adelman MW, et al. Open Forum Infect Dis. 2017 Dec 23;5(1):ofx269. doi: 10.1093/ofid/ofx269. eCollection 2018 Jan. Open Forum Infect Dis. 2017. PMID: 29399596 Free PMC article. - Rolling Out Xpert® MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems Strengthening.
Pathmanathan I, Date A, Coggin WL, Nkengasong J, Piatek AS, Alexander H. Pathmanathan I, et al. Afr J Lab Med. 2017 Mar 31;6(2):460. doi: 10.4102/ajlm.v6i2.460. Afr J Lab Med. 2017. PMID: 28785533 Free PMC article.
References
- ATS/CDC/IDSA. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161(4):1376–95. - PubMed
- World Health Organization. The global plan to stop TB 2011–2015: transforming the fight towards elimination of tuberculosis. World Health Organization; Geneva: 2010. WHO/HTM/STB/2010.2. Available from: www.stoptb.org/global/plan/
- Gomez-Pastrana D. Diagnosis of pulmonary tuberculosis in children. J Infect Dis Therap. 2013;1:17–24.
- Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J. 2014;43(6):1793–6. Describes potential market for a rapid tuberculosis (TB) test such as Xpert. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources